SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Noble James

(Last) (First) (Middle)
FLAT 12, VICTORIA GARDENS, 15 MARSTON
FERRY ROAD

(Street)
OXFORD X0 OX2 7EF

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2016
3. Issuer Name and Ticker or Trading Symbol
Adaptimmune Therapeutics PLC [ ADAP ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares with a nominal value of GBP0.001 per share 9,972,600 D
Ordinary Shares with a nominal value of GBP0.001 per share(1) 1,200,000 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Option to purchase Ordinary Shares (2) 03/31/2024 Ordinary Shares 1,335,000 0.1671(5) D
Option to purchase Ordinary Shares (3) 04/14/2024 Ordinary Shares 438,100 0.1671(6) D
Option to purchase Ordinary Shares (4) 12/19/2024 Ordinary Shares 3,500,000 0.5308(7) D
Explanation of Responses:
1. Represented by 200,000 American Depositary Shares ("ADSs") held by Mr. Noble. Mr. Noble holds these Ordinary Shares in the form of ADSs. Each ADS represents six Ordinary Shares of Adaptimmune Therapeutics plc.
2. Currently exercisable as to 915,000 Ordinary Shares and will be exercisable as to the remainder ratably in annual installments on the thirty first of March from March 31, 2016 through March 31, 2018.
3. Currently exercisable as to 109,500 Ordinary Shares and will be exercisable as to 109,500 Ordinary Shares on each of April 14, 2016 and April 14, 2017 and as to 109,600 Ordinary Shares on April 14, 2018.
4. Exercisable as to 875,000 Ordinary Shares on December 19, 2015 and will be exercisable as to the remainder in monthly installments of 72,900 Ordinary Shares on the nineteenth of each month from January 19, 2016 through November 19, 2018, and in one installment of 73,500 Ordinary Shares on December 19, 2018.
5. The exercise price was converted from GBP0.112 based on the noon buying rate of the Federal Reserve Bank of New York for the U.S. dollar on the date of grant. The actual exercise price will be the pounds sterling amount regardless of the exchange rate on the date of grant or of exercise.
6. The exercise price was converted from GBP0.112 based on the noon buying rate of the Federal Reserve Bank of New York for the U.S. dollar on the date of grant. The actual exercise price will be the pounds sterling amount regardless of the exchange rate on the date of grant or of exercise.
7. The exercise price was converted from GBP0.3557 based on the noon buying rate of the Federal Reserve Bank of New York for the U.S. dollar on the date of grant. The actual exercise price will be the pounds sterling amount regardless of the exchange rate on the date of grant or of exercise.
/s/ James Julian Noble Name: James Julian Noble 01/04/2016
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.